These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38214982)

  • 1. Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.
    Shen L; Wang B; Wang SP; Ji SK; Fu MJ; Wang SW; Hou WQ; Dai XJ; Liu HM
    J Med Chem; 2024 Jan; 67(2):922-951. PubMed ID: 38214982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances of LSD1/KDM1A inhibitors for disease therapy.
    Zhang C; Wang Z; Shi Y; Yu B; Song Y
    Bioorg Chem; 2023 May; 134():106443. PubMed ID: 36857932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
    Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
    J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
    Fang Y; Liao G; Yu B
    J Hematol Oncol; 2019 Dec; 12(1):129. PubMed ID: 31801559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
    Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
    J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials.
    Noce B; Di Bello E; Fioravanti R; Mai A
    Front Pharmacol; 2023; 14():1120911. PubMed ID: 36817147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research progress of LSD1-based dual-target agents for cancer therapy.
    Yang X
    Bioorg Med Chem; 2024 Mar; 101():117651. PubMed ID: 38401457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysine-Specific Demethylase 1 (LSD1) Inhibitors: Peptides as an Emerging Class of Therapeutics.
    Baby S; Shinde SD; Kulkarni N; Sahu B
    ACS Chem Biol; 2023 Oct; 18(10):2144-2155. PubMed ID: 37812385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
    Hosseini A; Minucci S
    Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
    Zhang S; Liu M; Yao Y; Yu B; Liu H
    Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
    Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
    Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances toward LSD1 inhibitors for cancer therapy.
    Fu X; Zhang P; Yu B
    Future Med Chem; 2017 Jul; 9(11):1227-1242. PubMed ID: 28722477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors.
    Duan Y; Yu T; Jin L; Zhang S; Shi X; Zhang Y; Zhou N; Xu Y; Lu W; Zhou H; Zhu H; Bai S; Hu K; Guan Y
    Eur J Med Chem; 2023 Jun; 254():115367. PubMed ID: 37086699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising natural lysine specific demethylase 1 inhibitors for cancer treatment: advances and outlooks.
    Li ZR; Gu MZ; Xu X; Zhang JH; Zhang HL; Han C
    Chin J Nat Med; 2022 Apr; 20(4):241-257. PubMed ID: 35487595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
    Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
    Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020).
    Zheng YC; Liu YJ; Gao Y; Wang B; Liu HM
    Recent Pat Anticancer Drug Discov; 2022; 17(1):9-25. PubMed ID: 34323202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting LSD1 in cancer: Molecular elucidation and recent advances.
    Cai W; Xiao C; Fan T; Deng Z; Wang D; Liu Y; Li C; He J
    Cancer Lett; 2024 Aug; 598():217093. PubMed ID: 38969160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
    Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
    Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.
    Zheng YC; Yu B; Chen ZS; Liu Y; Liu HM
    Epigenomics; 2016 May; 8(5):651-66. PubMed ID: 27102879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
    Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
    Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.